Aspreva Pharmaceuticals Corporation today announced the completion of the plan of arrangement with Galencia Group, pursuant to which Galencia, through a wholly-owned Canadian subsidiary, acquired all outstanding shares of Aspreva for US $26.00 per share in cash.

With the completion of the plan of arrangement, Aspreva will delist its shares from the NASDAQ on January 3, 2008 and the Toronto Stock Exchange on January 7, 2008.

Effective immediately, Aspreva Pharmaceuticals will now be named Vifor Pharma Aspreva.